Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2025)

Maravai Lifesciences Holdings has reported Gross Margin over the past 6 years, most recently at 25.75% for Q4 2025.

  • Quarterly results put Gross Margin at 25.75% for Q4 2025, down 853.0% from a year ago — trailing twelve months through Dec 2025 was 18.3% (down 2349.0% YoY), and the annual figure for FY2025 was 18.3%, down 2349.0%.
  • Gross Margin for Q4 2025 was 25.75% at Maravai Lifesciences Holdings, up from 13.58% in the prior quarter.
  • Over the last five years, Gross Margin for MRVI hit a ceiling of 84.55% in Q2 2022 and a floor of 13.58% in Q3 2025.
  • Median Gross Margin over the past 5 years was 49.67% (2023), compared with a mean of 54.05%.
  • Biggest five-year swings in Gross Margin: skyrocketed 2783bps in 2021 and later tumbled -4735bps in 2023.
  • Maravai Lifesciences Holdings' Gross Margin stood at 82.87% in 2021, then dropped by -11bps to 73.99% in 2022, then fell by -29bps to 52.65% in 2023, then tumbled by -35bps to 34.28% in 2024, then fell by -25bps to 25.75% in 2025.
  • The last three reported values for Gross Margin were 25.75% (Q4 2025), 13.58% (Q3 2025), and 16.39% (Q2 2025) per Business Quant data.